Evidence map›Paper›PMID 28329057›Full record

ArticleJAMA cardiology2017

Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease.

Jing Chen, Matthew J Budoff, Muredach P Reilly, Wei Yang, Sylvia E Rosas, Mahboob Rahman, Xiaoming Zhang, Jason A Roy, Eva Lustigova, Lisa Nessel and 8 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in JAMA cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 208 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed, 5 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06903689 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Exploring the Potential Effect of Pentoxifylline in Mitigating Vascular Calcification in Chronic Kidney Disease Patients

TypeinterventionalSponsorMansoura UniversityRan2025 to 2025Enrolled80ConditionsChronic Kidney Disease, Vascular Calcification, Kidney Failure, ChronicArmsPentoxifylline 400 MG Oral Tablet, Conventional Medications for Chronic Kidney Disease
NCT07654231 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2026 to 2027Enrolled60ConditionsChronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, DyslipidemiaArmsLow-dose Colchicine at 0.5mg daily, Usual Care
3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 5 syntheses or guidelines pooled it, 354 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018
    Trial
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Article

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 1 country.

Jing ChenDepartment of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana2Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana.
Matthew J BudoffLA BioMed at Harbor-UCLA Medical Center, Los Angeles, California.
Muredach P ReillyDepartment of Medicine, Division of Cardiology, Columbia University, New York, New York.
Wei YangDepartment of Biostatistics and Epidemiology, School of Medicine, University of Pennsylvania, Philadelphia.
Sylvia E RosasJoslyn Diabetic Center, Harvard Medical School, Boston, Massachusetts.
Mahboob RahmanDepartment of Medicine, University Hospitals of Case Western Reserve University, Cleveland, Ohio.
Xiaoming ZhangDepartment of Biostatistics and Epidemiology, School of Medicine, University of Pennsylvania, Philadelphia.
Jason A RoyDepartment of Biostatistics and Epidemiology, School of Medicine, University of Pennsylvania, Philadelphia.
Eva LustigovaDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana.
Lisa NesselDepartment of Biostatistics and Epidemiology, School of Medicine, University of Pennsylvania, Philadelphia.
Virginia FordDepartment of Medicine, School of Medicine, University of Pennsylvania, Philadelphia.
Dominic RajDepartment of Medicine, School of Medicine, George Washington University, Washington, DC.
Anna C PorterDepartment of Medicine, University of Illinois Hospital and Health Sciences System, Chicago.
Elsayed Z SolimanDepartment of Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Jackson T WrightDepartment of Medicine, University Hospitals of Case Western Reserve University, Cleveland, Ohio.
Myles WolfDepartment of Medicine, School of Medicine, Duke University, Durham, North Carolina.
Jiang HeDepartment of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana2Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana.
CRIC Investigators
University of Pennsylvania · USTulane University · USUniversity Hospitals of Cleveland · USColumbia University · USDuke University · USGeorge Washington University · USHarvard University · USThe Lundquist Institute · USUniversity of Illinois Hospital & Health Sciences System · USWake Forest University · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7M
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Ning Liu · 2016 to 2026
$25.3M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, PANDURANGA S · 2001 to 2025
$16.9M
Proposal for a Chicago-CRIC Clinical CenterU01DK060980 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LASH, JAMES P. · 2001 to 2025
$15.4M
Tulane Clinical Center for Chronic Renal Insufficiency Cohort StudyU01DK060963 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI CHEN, JING, HAMM, L LEE · 2001 to 2025
$13.9M
Hispanic Chronic Renal Insufficiency Cohort(CRIC) StudyR01DK072231 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LASH, JAMES P. · 2005 to 2021
$10.9M
A pilot trial of an intervention to support initial type 2 diabetes selfmanagement among younger adults with children.R01DK139225 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Anjali Gopalan · 2025 to 2026
$649k
NCATS NIH HHS UL1 TR002240NCRR NIH HHS UL1 RR024986NIDDK NIH HHS R01 DK072231NIDDK NIH HHS R01 DK139225NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061028NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

Importance: Coronary artery calcification (CAC) is highly prevalent in dialysis-naive patients with chronic kidney disease (CKD). However, there are sparse data on the association of CAC with subsequent risk of cardiovascular disease and all-cause mortality in this population. Objective: To study the prospective association of CAC with risk of cardiovascular disease and all-cause mortality among dialysis-naive patients with CKD. Design, Setting, and Participants: The prospective Chronic Renal Insufficiency Cohort study recruited adults with an estimated glomerular filtration rate of 20 to 70 mL/min/1.73 m2 from 7 clinical centers in the United States. There were 1541 participants without cardiovascular disease at baseline who had CAC scores. Exposures: Coronary artery calcification was assessed using electron-beam or multidetector computed tomography. Main Outcomes and Measures: Incidence of cardiovascular disease (including myocardial infarction, heart failure, and stroke) and all-cause mortality were reported every 6 months and confirmed by medical record adjudication. Results: During an average follow-up of 5.9 years in 1541 participants aged 21 to 74 years, there were 188 cardiovascular disease events (60 cases of myocardial infarction, 120 heart failures, and 27 strokes; patients may have had >1 event) and 137 all-cause deaths. In Cox proportional hazards models adjusted for age, sex, race, clinical site, education level, physical activity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, use of antihypertensive treatment, current cigarette smoking, diabetes status, body mass index, C-reactive protein level, hemoglobin A1c level, phosphorus level, troponin T level, log N-terminal pro-B-type natriuretic peptide level, fibroblast growth factor 23 level, estimated glomerular filtration rate, and proteinuria, the hazard ratios associated with per 1 SD log of CAC were 1.40 (95% CI, 1.16-1.69; P < .001) for cardiovascular disease, 1.44 (95% CI, 1.02-2.02; P = .04) for myocardial infarction, 1.39 (95% CI, 1.10-1.76; P = .006) for heart failure, and 1.19 (95% CI, 0.94-1.51; P = .15) for all-cause mortality. In addition, inclusion of CAC score led to an increase in the C statistic of 0.02 (95% CI, 0-0.09; P < .001) for predicting cardiovascular disease over use of all the above-mentioned established and novel cardiovascular disease risk factors. Conclusions and Relevance: Coronary artery calcification is independently and significantly related to the risks of cardiovascular disease, myocardial infarction, and heart failure in patients with CKD. In addition, CAC improves risk prediction for cardiovascular disease, myocardial infarction, and heart failure over use of established and novel cardiovascular disease risk factors among patients with CKD; however, the changes in the C statistic are small.

Indexed as

AdultAgedCardiovascular DiseasesCause of DeathCohort StudiesComorbidityCoronary Artery DiseaseFemaleHeart FailureHumansIncidenceMaleMiddle AgedMortalityMyocardial InfarctionProportional Hazards Models

Identifiers

PMID28329057
PMCPMC5798875
OpenAlexW2603645732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.